Multisensory Room Therapy for Stress and Sensory Regulation in Children With Autism and Their Caregivers
Multidimensional Study of Child and Parental Stress in Autism Spectrum Disorder After a Multisensory Intervention: Biomarkers, Sensory Responses and Clinical Assessment. A Randomised Controlled Trial
The goal of this clinical trial is to learn whether therapy in a multisensory room improves sensory processing, behavioural and attentional regulation and stress in children aged 3 to 12 years with autism spectrum disorder (support level 2-3), and whether it reduces stress in their main caregivers. The main question it aims to answer is: does sensory processing (Sensory Profile 2) change more after 8 weeks of multisensory room therapy than after 8 weeks of standard behavioural therapy? Researchers will also compare executive function, attention and behaviour, parental stress, and stress-related biomarkers in saliva (cortisol, oxytocin and inflammatory interleukins). They will also record physiological stress signals in caregivers (heart rate, skin conductance, breathing and temperature).
Sixty children will be randomly assigned to one of two groups. Children in the first group will receive two individual 45-minute multisensory room sessions per week for 8 weeks. Children in the second group will receive standard behavioural therapy with psychology and speech therapy, without multisensory stimulation. Caregivers will complete questionnaires and give saliva samples before and after the 8-week programme.
Studieöversikt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljerad beskrivning
Background. Sensory processing differences are highly prevalent in autism spectrum disorder (ASD) and are associated with anxiety, emotional dysregulation and lower adaptive functioning. Children with ASD show atypical activation of the hypothalamic-pituitary-adrenal axis and elevated pro-inflammatory cytokines. Parents of children with ASD report high parenting stress. Multisensory environments (Snoezelen®) are widely used to support self-regulation, but controlled trials with objective outcomes are scarce.
Design. Randomised, controlled, parallel-group trial with pre-post assessment. Families with a child aged 3-12 years with ASD (support level 2-3) attending the Centre de Teràpia Interfamiliar (Elche, Spain) are randomised 1:1. Randomisation is stratified by age, sex and the primary outcome, in blocks of two, and the sequence is concealed. Outcome assessors are blinded to group allocation; therapists cannot be blinded.
Interventions. Multisensory group: 16 individual 45-minute sessions (2 per week for 8 weeks) in a multisensory room, delivered by occupational therapists trained in multisensory stimulation in ASD. Each session follows a semi-structured protocol: welcome and adaptation (5 min); guided sensory regulation with graded visual, auditory, tactile, vestibular and proprioceptive stimuli (15-20 min); active participation and control of the environment (10-15 min); and closure with return to calm (5 min). Control group: 45-minute sessions of standard behavioural therapy with psychology and speech therapy, under standard lighting, without therapeutic multisensory stimuli and with the same therapist presence.
Assessments. Baseline (T0): child saliva biomarkers; caregiver-reported Sensory Profile 2, BRIEF-P/BRIEF-2, Conners scales and PSI-SF; caregiver saliva and hair biomarkers; and caregiver physiological recording (BIOPAC MP36R). During the intervention (T1): child saliva before and after each session, and a structured observational self-regulation record after each session. After 8 weeks (T2): caregiver-reported scales, caregiver biomarkers and physiological recording. Salivary cortisol, oxytocin, IL-6, IL-1β, IL-17A and TNF-α are analysed by ELISA at Universidad CEU Cardenal Herrera.
Setting and data. The study is conducted at the Centre de Teràpia Interfamiliar (Elche, Spain) in collaboration with the Neurobiology research group of Universidad CEU Cardenal Herrera. Data are pseudonymised and handled in accordance with the GDPR and Spanish Organic Law 3/2018.
Studietyp
Studietyp
Inskrivning (Beräknad)
Inskrivning
Fas
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
Studiekontakt
- Namn: SERGIO MONTERO-NAVARRO, PhD
- Telefonnummer: 67604 +34965426486
- E-post: sergio.montero@uchceu.es
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria (children):
- Clinical diagnosis of autism spectrum disorder, support level 2 or 3 (DSM-5).
- Age 3 to 12 years.
- Attending and registered at the Centre de Teràpia Interfamiliar.
- Stable therapeutic and pharmacological treatment during the study period.
- Able to tolerate entering and remaining in the multisensory room.
- Written informed consent from parents or legal guardians.
Exclusion Criteria (children):
- Uncontrolled epilepsy.
- Recent changes in medication.
- Acute illness at the time of assessment.
- Severe motor or sensory disability preventing participation in the intervention.
- Persistent refusal of, or inability to adapt to, the multisensory room.
Inclusion Criteria (caregivers):
- Adult (18 years or older) main caregiver of an enrolled child.
- Sufficient cognitive capacity to understand the informed consent.
Exclusion Criteria (caregivers):
- Acute illness at the time of assessment.
- Severe motor or sensory disability preventing participation in the assessments.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Antal vapen
Vapen och interventioner
Deltagargrupp / ArmDeltagargrupp / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Experimentell: Multisensory room therapy
Children with ASD receive 8 individual 45-minute sessions (1 per week for 8 weeks) in a multisensory room. Their caregivers complete assessments and provide biological samples. |
Semi-structured individual session in a multisensory (Snoezelen®) room delivered by occupational therapists trained in multisensory stimulation in ASD: (1) welcome and adaptation, 5 min, with dim light and no loud sounds; (2) guided sensory regulation, 15-20 min, with graded visual, auditory, tactile, vestibular and proprioceptive stimuli adjusted to the child's profile; (3) active participation and control of the environment, 10-15 min, in which the child chooses or modulates stimuli; (4) closure and return to calm, 5 min. Two sessions per week for 8 weeks.
Andra namn:
|
|
Aktiv komparator: Standard behavioural therapy
Children with ASD receive 45-minute sessions of standard behavioural therapy (psychology and speech therapy) without multisensory stimulation, over the same 8-week period. Their caregivers complete the same assessments. |
45-minute session with psychology and speech therapy addressing children with ASD support level 2-3, under standard lighting, without therapeutic multisensory stimuli, and with the same therapist presence as the experimental arm. |
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in sensory hyper-reactivity (Sensory Profile 2, Sensitivity quadrant)
Tidsram: Baseline and week 8
|
Sensory Profile 2 - Child form, completed by the main caregiver. Raw score of the Sensitivity quadrant (19 items, each rated from 1 = almost never to 5 = almost always; range 19-95). Higher scores indicate more frequent sensory hyper-reactivity (worse outcome). |
Baseline and week 8
|
Sekundära resultatmått
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in executive function (Behavior Rating Inventory of Executive Function, BRIEF-P / BRIEF-2)
Tidsram: Baseline and week 8
|
Behavior Rating Inventory of Executive Function - Preschool Version (BRIEF-P, ages 3-5) or BRIEF-2 parent form (ages 5-12), completed by the main caregiver. Global Executive Composite raw score (63 items rated 1-3; range 63-189). Higher scores indicate greater executive dysfunction (worse outcome). |
Baseline and week 8
|
|
Change in emotional and behavioural problems (SENA, Global Problems Index)
Tidsram: Baseline and week 8
|
Child and Adolescent Assessment System (SENA), family-report form for ages 3-6 or 6-12, completed by the main caregiver. Global Problems Index, T-score (normative mean 50, SD 10; range of risk 65-69; significative range of risk: >70). Higher scores indicate more emotional and behavioural problems (worse outcome). |
Baseline and week 8
|
|
Parenting stress (PSI-SF)
Tidsram: Baseline and week 8
|
PSI-SF is a 36-item, self-report measure of parenting stress. It includes three subscales: Parental Distress (PD; e.g, "I feel trapped by my responsibilities as a parent", "I feel lonely and without friends"), Parent-Child Dysfunctional Interaction (PCDI; e.g, "Sometimes I feel my child doesn't like me and doesn't want to be close to me", "When I do things for my child I get the feeling that my efforts are not appreciated" ), and Difficult Child (DC; e.g, "My child makes more demands on me than most children", "My child gets upset easily over the smallest thing"). Each subscale consists of 12 items rated from 1 (strongly disagree) to 5 (strongly agree), with subscales scores ranging from 12 to 60. A Total score is calculated by summing the three subscales scores, ranging from 36 to 180. Scores of 90 or above may indicate a clinical level of stress. |
Baseline and week 8
|
|
Child salivary cortisol (ng/mL)
Tidsram: Baseline and before/after each session, weeks 1-8
|
ELISA Kits ' Cortisol ELISA Kits Human Cortisol Competitive ELISA Kit ,Invitrogen. Quantification of cortisol: RT-2100C microplate reader, which is a general-purpose microprocessor-controlled photometric system designed to read and calculate biomarker assay results (optic ivymen system) |
Baseline and before/after each session, weeks 1-8
|
|
Child salivary oxytocin (pg/mL)
Tidsram: Baseline and before/after each session, weeks 1-8
|
ELISA Kits ' Cortisol ELISA Kits Human Cortisol Competitive ELISA Kit ,Invitrogen. Quantification of oxytocin: RT-2100C microplate reader, which is a general-purpose microprocessor-controlled photometric system designed to read and calculate biomarker assay results (optic ivymen system) |
Baseline and before/after each session, weeks 1-8
|
|
Child salivary pro-inflammatory cytokines
Tidsram: Baseline and before/after each session, weeks 1-8
|
Salivary IL-6, IL-1β, IL-17A and TNF-α (pg/mL, ELISA). |
Baseline and before/after each session, weeks 1-8
|
|
Caregiver stress biomarkers - Salivary cortisol (ng/mL)
Tidsram: Baseline and week 8
|
Baseline and week 8
|
|
|
Caregiver stress biomarkers - oxytocin (pg/mL)
Tidsram: Baseline and week 8
|
Baseline and week 8
|
|
|
Caregiver stress biomarkers - IL-6, IL-1β, IL-17A and TNF-α (pg/mL) (ELISA)
Tidsram: Baseline and week 8
|
Baseline and week 8
|
|
|
Caregiver stress biomarkers - hair cortisol (pg/mg)
Tidsram: Baseline and week 8
|
Baseline and week 8
|
|
|
In-session self-regulation (observational record)
Tidsram: After each session, weeks 1-8
|
Therapist-rated 8-item record (0-3 per item; total 0-24). Higher scores indicate greater self-regulation difficulty. |
After each session, weeks 1-8
|
|
Heart rate and heart rate variability (LF, HF, LF/HF ratio). BIOPAC MP36R device
Tidsram: Baseline and week 8
|
During a recording of about 30 minutes |
Baseline and week 8
|
|
Galvanic response by means of Skin conductance (SC). micro-siemens or micro-omhios. BIOPAC MP36R device
Tidsram: Baseline and week 8
|
During a recording of about 30 minutes |
Baseline and week 8
|
|
Breathing rate (breaths per minute). BIOPAC MP36R device
Tidsram: Baseline and week 8
|
During a recording of about 30 minutes |
Baseline and week 8
|
|
Skin temperature (ºC). BIOPAC MP36R device
Tidsram: Baseline and week 8
|
During a recording of about 30 minutes |
Baseline and week 8
|
Andra resultatmått
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Adverse events
Tidsram: Weeks 1-8
|
Number of children with behavioural crises, sensory overload requiring session interruption, or other adverse events, by group. |
Weeks 1-8
|
Samarbetspartners och utredare
Sponsor
Sponsor
Samarbetspartners
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Studiestart
Primärt slutförande (Beräknad)
Primärt slutförande
Avslutad studie (Beräknad)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
Andra studie-ID-nummer
- CEEI26/863
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Coded data may be shared only for purposes consistent with the study and under confidentiality guarantees; no international transfers are planned.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .